slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 229,021-229,050
Pages 10,126
Rows per page 30
Component
229,021-229,050 of 303,780
08
The slide uses a process-oriented flow diagram to explain the therapeutic strategy.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
09
Arbutus Biopharma | Investor Presentation Deck | 26 slidesArbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
10
The slide highlights the mechanism of action and key benefits of the drug candidate.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
11
Data presented at EASL 2022, AASLD 2022, GHS 2023.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
12
Data presented at EASL 2022. Shows dual-axis line charts for viral load/ALT and bar charts for T-cell frequency.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
13
Arbutus Biopharma | Investor Presentation Deck | 26 slidesArbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
14
The slide outlines a clinical trial protocol with specific patient counts (n=12, n=8) and timeline milestones (weeks 1, 24, 28, 40, 52).Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
15
Data presented at EASL 2023. Includes both a summary table of mean changes and individual patient trajectory charts.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
16
Shows two parallel study arms with randomization at week 24/26.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
17
Data presented at AASLD 2023; includes both a summary table and a longitudinal line chart with error bars.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
18
Data presented at AASLD 2023. Shows ELISpot results for T cell responses and HBsAg levels.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
20
Arbutus Biopharma | Investor Presentation Deck | 26 slidesArbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
21
The slide uses a three-column layout to explain the scientific basis and product advantages.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
22
Includes both in vitro (IFN-y fold increase) and in vivo (MC38 tumor model) efficacy data.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
23
The slide outlines a multi-part clinical trial structure with specific cohort sizes and dosing progression.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
24
Includes a footnote regarding the 3/21/2023 Court Scheduling Order.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
25
The slide includes a financial disclaimer regarding cash balance and burn.Arbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
26
Arbutus Biopharma | Investor Presentation Deck | 26 slidesArbutus Biopharma | Investor Presentation Deck | 26 slides · Arbutus Biopharma
Pitch deck Investor relations Beat · Solution1 hit
01
argenx SE | Investor Conference Presentation Deck | 27 slidesargenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Humble Origins1 hit
02
argenx SE | Investor Conference Presentation Deck | 27 slidesargenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Humble Origins1 hit
04
The slide uses a large portrait of a patient to build emotional connection and credibility.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Early Struggles1 hit
05
Uses a concentric circle/horizon layout to represent different stages of development and commercialization.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Early StrugglesLoop · Why Now1 hit
06
The slide uses a circular/concentric layout to represent the 'horizon' of opportunities, with the pipeline on the left and commercial/development milestones on the right.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Early StrugglesLoop · Why Now1 hit
07
The slide uses an infinity-loop style diagram to connect three pillars of leadership.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Rising SuccessLoop · Why Now1 hit
08
The slide highlights clinical outcomes (QoL, MG-ADL scores), treatment protocols (steroid tapering), patient support (My VYVGART Path), and economic value (cost/benefit vs IVIg).argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Rising SuccessLoop · Why Now1 hit
10
The slide uses a stacked bar/arrow hybrid to illustrate growth. The data points are 6,000 (US patients), 17,000 (RoW TAM), and 31,000 (US TAM).argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Rising SuccessLoop · Why Now1 hit
11
The slide uses a two-stage framework to present clinical data and patient outcomes.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Rising SuccessLoop · Why Now1 hit
12
Uses a visual metaphor of a patient partially submerged to represent 'unseen suffering'.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Rising SuccessLoop · Why Now1 hit
13
The slide highlights the progression of delivery technology enabled by the ENHANZE license.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Rising SuccessLoop · Why Now1 hit
14
Uses a pyramid-like growth visualization to represent expanding market opportunities.argenx SE | Investor Conference Presentation Deck | 27 slides · argenx
Conference presentation Investor relations Beat · Rising SuccessLoop · Why Now1 hit